Bringing an Artificial Pancreas to Market
FDA study proposed, open for public comments.
As noted in the diaTribe #38 letter from the editor, the FDA released its much awaited draft guidance on the artificial pancreas (AP) by the promised December 1 deadline. This document provides the FDA's recommendations and suggestions for carrying out artificial pancreas studies, which will culminate in an FDA review and hopefully approval of the system for use by patients. In the months leading up to the guidance release, JDRF put substantial pressure on the FDA. We were happy to see that the agency incorporated many of JDRF's suggestions and hope that the FDA's emphasis on a reasonable, flexible development and study process ultimately translates into faster regulatory approval of an AP.
The FDA has proposed a three-stage study progression to bring the AP to market: early feasibility studies, transitional studies, and pivotal studies. According to the guidance document, feasibility and transitional studies will require small numbers of participants, be of short duration, and take place in clinical research settings with careful medical supervision. The final pivotal study to approve the device will be at least six months in length and take place in a real-world setting with participants going about their daily lives. Whenever the FDA approves a medical device, it needs evidence to ensure that it is both safe and effective. Studies to approve the AP will thus be designed and evaluated with this perspective in mind.
The pivotal study to approve an AP will compare two groups: the "control group" will use a standard insulin pump and CGM as they are used today, i.e., patients will manually bolus and set basal rates. They will be compared to a group wearing an artificial pancreas system that automatically changes insulin doses based on the CGM value. The first generations of the AP will be "control-to-range," meaning the system will aim to keep patients in a range of glucose values (e.g., 70-180 mg/dl) rather than targeting a single number. These are also called "hybrid closed-loop systems" because patients will still need to bolus and set basal rates, but the AP will automatically increase or decrease basal insulin if the blood sugar is trending too high or too low. In the future, more advanced systems will require less patient intervention and will target a set glucose value instead of a range (e.g., 100 mg/dl); however, better CGM, even faster-acting insulin, and even glucagon (a hormone that quickly increases blood glucose) will likely be needed.
To gain FDA approval, studies must show that those wearing the artificial pancreas do not increase their A1C compared to those wearing a traditional pump and CGM (this is known as ‘non-inferiority'). But the FDA could allow increases in A1c as long as AP-wearing patients have other improvements (e.g., a reduction in hypoglycemia). In addition to non-inferiority, superiority studies can demonstrate that the artificial pancreas is better than wearing just a standard insulin pump and CGM. For this sort of claim, the artificial pancreas must improve A1C by at least 0.4% and/or improve measures of hypo- or hyperglycemia (as measured by CGM) by at least 30 percent.
Salsa Roja Artichoke Tartlets Chicken Salad Sandwich Two Layer Salami and Ham Sandwich Apricot-Almond Granola Roasted Striped Bass Millet with Water Chestnuts Classic Onion Rings Dark Chocolate Brownies Crab Salad
Well maybe not so much a furor as a controversy. The question, bluntly put, is whether or not a single HbA1c reading should be sufficient and adequate to diagnose diabetes — and whether the conditions under which the test was conducted should have any bearing on the diagnostic or non-diagnostic value of the test. The lede from